Allurion’s Non-Invasive Weight-Loss Balloon Debuts at Ruijin Hospital’s Hainan Subsidiary
US-based Allurion’s (NYSE: ALUR) weight-loss intragastric balloon has been first applied in Shanghai Ruijin Hospital’s...
Obesity
Eli Lilly Expands Portfolio with Acquisitions of Sigilon Therapeutics and Versanis Bio
Eli Lilly (NYSE: LLY) has completed the separate purchases of US compatriots Sigilon Therapeutics (NASDAQ:...
Novo Nordisk to Acquire Inversago Pharma in a Deal Valued Up to USD 1.1 Billion
Denmark’s leading pharmaceutical company, Novo Nordisk (NYSE: NVO), has reached an agreement to acquire Canada-based...
Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales
Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the...
Novo Nordisk’s Wegovy Demonstrates 20% Reduction in Cardiovascular Events in SELECT Trial
Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has released topline data supporting the use...
Shanghai Benemae’s Benaglutide Approved by NMPA for Adult Weight Management in China
The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by...
Sciwind Biosciences Leads China’s Anti-Obesity Drug Market with GLP-1 Analog Ecnoglutide
Sino-US biotech Sciwind Biosciences Co., Ltd has positioned itself as a frontrunner in China’s race...
AstraZeneca Enters Three-Year Collaboration with Cholesgen for Metabolic Disease Therapies
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has signed a three-year collaboration agreement with China-based...
Sino Biopharmaceutical Secures Exclusive Rights to Gmax Biopharm’s GMA106 in Greater China
Sino Biopharmaceutical Ltd (HKG: 1177) through its subsidiary Chia Tai Tianqing Pharmaceutical Co., Ltd, has...
Eccogene Secures $25 Million in Series B Financing to Advance Metabolic Disease Therapies
Sino-US firm Eccogene Inc. has announced the closure of a Series B financing round, raising...